Dianthus Therapeutics, Inc. /DE/ (DNTH)
| Market Cap | 4.59B+136.3% |
| Revenue (ttm) | n/a-60.8% |
| Net Income | n/a+73.9% |
| EPS | n/a+96.0% |
| Shares Out | 55.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,231.855 |
| Open | 84.73 |
| Previous Close | 84.88 |
| Day's Range | 81.28 - 84.73 |
| 52-Week Range | 32.22 - 117.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 126.83(+54.45%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DNTH stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DNTH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DNTH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DNTH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DNTH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DNTH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DNTH
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $174.64M |
| XBIState Street SPDR S&P Biotech ETF | $123.48M |
| IWMiShares Russell 2000 ETF | $105.39M |
| VXFVanguard Extended Market ETF | $48.98M |
| IWOiShares Russell 2000 Growth ETF | $37.58M |
| VTWOVanguard Russell 2000 ETF | $28.72M |
Estimated from each fund’s disclosed top holdings × AUM
DNTH Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DNTH’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score